N-Acetylaspartate and neurofilaments as biomarkers of axonal damage in patients with progressive forms of multiple sclerosis
- 17 September 2014
- journal article
- Published by Springer Science and Business Media LLC in Zeitschrift für Neurologie
- Vol. 261 (12), 2338-2343
- https://doi.org/10.1007/s00415-014-7507-4
Abstract
Primary and secondary progressive forms of multiple sclerosis (PPMS and SPMS) have different pathological characteristics. However, it is unknown whether neurodegenerative mechanisms are shared. We measured cerebrospinal fluid (CSF) levels of neurofilament (Nf) light and heavy isoforms and N-acetylaspartic acid (NAA) in 21 PP, 10 SPMS patients and 15 non-inflammatory neurological disease controls (NINDC). Biomarkers were related to Expanded Disability Status Scale (EDSS) and Multiple Sclerosis Severity Score (MSSS) over a long period of follow-up [median (interquartile range) 9 (5.5–12.5) years] in 19 PPMS and 4 SPMS patients, and to T2 lesion load, T1 lesion load, and brain parenchymal fraction at the time of lumbar puncture. Nf light was higher in PPMS (p < 0.005) and Nf heavy was increased in both SPMS and PPMS (p < 0.05 and p < 0.01) compared to NINDC, but were comparable between the two MS subtypes. Nf heavy was a predictor of the ongoing disability measured by MSSS (R 2 = 0.17, β = 0.413; p < 0.05). Conversely, Nf light was the only predictor of the EDSS annual increase (R 2 = 0.195, β = 0.441; p < 0.05). The frequency of abnormal biomarkers did not differ between the two MS progressive subtypes. Our data suggest that PP and SPMS likely share similar mechanisms of axonal damage. Moreover, Nf heavy can be a biomarker of ongoing axonal damage. Conversely, Nf light can be used as a prognostic marker for accumulating disability suggesting it as a good tool for possible treatment monitoring in the progressive MS forms.Keywords
This publication has 22 references indexed in Scilit:
- The impact of pre-analytical variables on the stability of neurofilament proteins in CSF, determined by a novel validated SinglePlex Luminex assay and ELISAJournal of Immunological Methods, 2014
- CSF neurofilament and N-acetylaspartate related brain changes in clinically isolated syndromeMultiple Sclerosis Journal, 2012
- Neurofilament heavy chain in CSF correlates with relapses and disability in multiple sclerosisNeurology, 2011
- A consensus protocol for the standardization of cerebrospinal fluid collection and biobankingNeurology, 2009
- Neurofilament ELISA validationJournal of Immunological Methods, 2009
- A single-center, randomized, double-blind, placebo-controlled study of interferon beta-1b on primary progressive and transitional multiple sclerosisMultiple Sclerosis Journal, 2009
- Greater loss of axons in primary progressive multiple sclerosis plaques compared to secondary progressive diseaseBrain, 2009
- Combination of CSF N -acetylaspartate and neurofilaments in multiple sclerosisNeurology, 2009
- Elevated neurofilament levels in neurological diseasesBrain Research, 2003
- Major differences in the dynamics of primary and secondary progressive multiple sclerosisAnnals of Neurology, 1991